Loading…

HLA-B 13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?

Antiepileptic drugs frequently cause cutaneous adverse reactions (cADRs). Numerous studies have reported associations between human leukocyte antigen (HLA) alleles and cADRs caused by single antiepileptic drug in Southern Han Chinese people. However, the relationship between the HLA allele and cADRs...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neurology 2019, Vol.10, p.614
Main Authors: Min, Fu-Li, Mao, Bi-Jun, Zheng, Zhong-Zheng, He, Na, Fan, Cui-Xia, Cai, Rui-Yan, Wang, Juan, Ou, Yang-Mei, Qin, Bing, Liao, Wei-Ping, Yi, Yong-Hong, Li, Ze, Shi, Yi-Wu
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page 614
container_title Frontiers in neurology
container_volume 10
creator Min, Fu-Li
Mao, Bi-Jun
Zheng, Zhong-Zheng
He, Na
Fan, Cui-Xia
Cai, Rui-Yan
Wang, Juan
Ou, Yang-Mei
Qin, Bing
Liao, Wei-Ping
Yi, Yong-Hong
Li, Ze
Shi, Yi-Wu
description Antiepileptic drugs frequently cause cutaneous adverse reactions (cADRs). Numerous studies have reported associations between human leukocyte antigen (HLA) alleles and cADRs caused by single antiepileptic drug in Southern Han Chinese people. However, the relationship between the HLA allele and cADRs sequentially induced by two or more antiepileptic drugs (AEDs-induced cross-reactivity) is unclear. To explore the associations between HLA alleles and AEDs-induced cross-reactivity, we prospectively recruited patients with AEDs-induced cross-reactivity from 2009 to 2017 and performed high-resolution genotyping to detect the HLA-A, B, C, and DRB1 alleles in patients for comparison with normal controls. To verify the important genotype, we compared its presence in patients with cross-reactivity to enlarged normal controls, and its presence in patients with carbamazepine (CBZ)-induced maculopapular exanthema (MPE) to CBZ-tolerant controls. Further, the important allele was replicated by meta-analysis. Twenty-three patients with AED-induced cross-reactivity and 500 healthy individuals were enrolled from Southern China. All patients had a mild rash without mucosal or systemic involvement. The HLA-B 13:01 allele was present in 34.78% (8/23) of patients, 14.60% (73/500) of healthy individuals, and 14.5% (763/5,270) healthy individuals, revealing a significant association (8/23 vs. 73/500; = 0.02; OR: 3.12; 95% CI: 1.28-7.62; 8/23 vs. 763/5,270; = 0.014; OR: 3.15; 95% CI: 1.33-7.46). HLA-B 13:01 was presented numerically higher in CBZ-induced MPE than that in CBZ-tolerant individuals without statistical significance (33/145, 22.76%, vs. 28/179, 15.64%; = 0.103). Meta-analysis revealed an association between HLA-B 13:01 and cADRs induced by single AEDs or/and non-AEDs in Chinese and Thai populations ( = 0.000). This study suggests that HLA-B 13:01 is potentially associated with AED-cADRs in general, possibly with stronger effect in cross-reactivity. Screening for HLA-B 13:01 prior to starting AEDs therapy may help to avoid cADRs. However, this association requires further analysis in a multi-center study with a larger sample size.
doi_str_mv 10.3389/fneur.2019.00614
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_31263447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31263447</sourcerecordid><originalsourceid>FETCH-LOGICAL-p93t-205727ed1f4ef7ea8a2dfca4d257ea926d2cbc776359f929c50a35052cea4b3b3</originalsourceid><addsrcrecordid>eNpNkE1Lw0AYhBdRbKm9e5L9A6n7mXR7kRg_UigIpfey2X23rqZJ2E0KxT9vpQrOZWZgeA6D0C0lM87n6t41MIQZI1TNCEmpuEBjmqYiYUzJy395hKYxfpCTuFI85ddoxClLuRDZGH2Vqzx5xJQvCMU6Yo3XPn7ivK6hBuzagPOm99D5GrreG_wUhl1Mlo0dDFhcDL1uoB0izu0BQgS8Bm163zZxgUu_e4dw5v2AitDGmJwHB98fH27QldN1hOmvT9Dm5XlTlMnq7XVZ5KukU7xPGJEZy8BSJ8BloOeaWWe0sEyemmKpZaYyWZZyqZxiykiiuSSSGdCi4hWfoLszthuqPdhtF_xeh-P27wT-DYI5YB0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>HLA-B 13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?</title><source>PubMed Central</source><creator>Min, Fu-Li ; Mao, Bi-Jun ; Zheng, Zhong-Zheng ; He, Na ; Fan, Cui-Xia ; Cai, Rui-Yan ; Wang, Juan ; Ou, Yang-Mei ; Qin, Bing ; Liao, Wei-Ping ; Yi, Yong-Hong ; Li, Ze ; Shi, Yi-Wu</creator><creatorcontrib>Min, Fu-Li ; Mao, Bi-Jun ; Zheng, Zhong-Zheng ; He, Na ; Fan, Cui-Xia ; Cai, Rui-Yan ; Wang, Juan ; Ou, Yang-Mei ; Qin, Bing ; Liao, Wei-Ping ; Yi, Yong-Hong ; Li, Ze ; Shi, Yi-Wu</creatorcontrib><description>Antiepileptic drugs frequently cause cutaneous adverse reactions (cADRs). Numerous studies have reported associations between human leukocyte antigen (HLA) alleles and cADRs caused by single antiepileptic drug in Southern Han Chinese people. However, the relationship between the HLA allele and cADRs sequentially induced by two or more antiepileptic drugs (AEDs-induced cross-reactivity) is unclear. To explore the associations between HLA alleles and AEDs-induced cross-reactivity, we prospectively recruited patients with AEDs-induced cross-reactivity from 2009 to 2017 and performed high-resolution genotyping to detect the HLA-A, B, C, and DRB1 alleles in patients for comparison with normal controls. To verify the important genotype, we compared its presence in patients with cross-reactivity to enlarged normal controls, and its presence in patients with carbamazepine (CBZ)-induced maculopapular exanthema (MPE) to CBZ-tolerant controls. Further, the important allele was replicated by meta-analysis. Twenty-three patients with AED-induced cross-reactivity and 500 healthy individuals were enrolled from Southern China. All patients had a mild rash without mucosal or systemic involvement. The HLA-B 13:01 allele was present in 34.78% (8/23) of patients, 14.60% (73/500) of healthy individuals, and 14.5% (763/5,270) healthy individuals, revealing a significant association (8/23 vs. 73/500; = 0.02; OR: 3.12; 95% CI: 1.28-7.62; 8/23 vs. 763/5,270; = 0.014; OR: 3.15; 95% CI: 1.33-7.46). HLA-B 13:01 was presented numerically higher in CBZ-induced MPE than that in CBZ-tolerant individuals without statistical significance (33/145, 22.76%, vs. 28/179, 15.64%; = 0.103). Meta-analysis revealed an association between HLA-B 13:01 and cADRs induced by single AEDs or/and non-AEDs in Chinese and Thai populations ( = 0.000). This study suggests that HLA-B 13:01 is potentially associated with AED-cADRs in general, possibly with stronger effect in cross-reactivity. Screening for HLA-B 13:01 prior to starting AEDs therapy may help to avoid cADRs. However, this association requires further analysis in a multi-center study with a larger sample size.</description><identifier>ISSN: 1664-2295</identifier><identifier>EISSN: 1664-2295</identifier><identifier>DOI: 10.3389/fneur.2019.00614</identifier><identifier>PMID: 31263447</identifier><language>eng</language><publisher>Switzerland</publisher><ispartof>Frontiers in neurology, 2019, Vol.10, p.614</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31263447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Min, Fu-Li</creatorcontrib><creatorcontrib>Mao, Bi-Jun</creatorcontrib><creatorcontrib>Zheng, Zhong-Zheng</creatorcontrib><creatorcontrib>He, Na</creatorcontrib><creatorcontrib>Fan, Cui-Xia</creatorcontrib><creatorcontrib>Cai, Rui-Yan</creatorcontrib><creatorcontrib>Wang, Juan</creatorcontrib><creatorcontrib>Ou, Yang-Mei</creatorcontrib><creatorcontrib>Qin, Bing</creatorcontrib><creatorcontrib>Liao, Wei-Ping</creatorcontrib><creatorcontrib>Yi, Yong-Hong</creatorcontrib><creatorcontrib>Li, Ze</creatorcontrib><creatorcontrib>Shi, Yi-Wu</creatorcontrib><title>HLA-B 13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?</title><title>Frontiers in neurology</title><addtitle>Front Neurol</addtitle><description>Antiepileptic drugs frequently cause cutaneous adverse reactions (cADRs). Numerous studies have reported associations between human leukocyte antigen (HLA) alleles and cADRs caused by single antiepileptic drug in Southern Han Chinese people. However, the relationship between the HLA allele and cADRs sequentially induced by two or more antiepileptic drugs (AEDs-induced cross-reactivity) is unclear. To explore the associations between HLA alleles and AEDs-induced cross-reactivity, we prospectively recruited patients with AEDs-induced cross-reactivity from 2009 to 2017 and performed high-resolution genotyping to detect the HLA-A, B, C, and DRB1 alleles in patients for comparison with normal controls. To verify the important genotype, we compared its presence in patients with cross-reactivity to enlarged normal controls, and its presence in patients with carbamazepine (CBZ)-induced maculopapular exanthema (MPE) to CBZ-tolerant controls. Further, the important allele was replicated by meta-analysis. Twenty-three patients with AED-induced cross-reactivity and 500 healthy individuals were enrolled from Southern China. All patients had a mild rash without mucosal or systemic involvement. The HLA-B 13:01 allele was present in 34.78% (8/23) of patients, 14.60% (73/500) of healthy individuals, and 14.5% (763/5,270) healthy individuals, revealing a significant association (8/23 vs. 73/500; = 0.02; OR: 3.12; 95% CI: 1.28-7.62; 8/23 vs. 763/5,270; = 0.014; OR: 3.15; 95% CI: 1.33-7.46). HLA-B 13:01 was presented numerically higher in CBZ-induced MPE than that in CBZ-tolerant individuals without statistical significance (33/145, 22.76%, vs. 28/179, 15.64%; = 0.103). Meta-analysis revealed an association between HLA-B 13:01 and cADRs induced by single AEDs or/and non-AEDs in Chinese and Thai populations ( = 0.000). This study suggests that HLA-B 13:01 is potentially associated with AED-cADRs in general, possibly with stronger effect in cross-reactivity. Screening for HLA-B 13:01 prior to starting AEDs therapy may help to avoid cADRs. However, this association requires further analysis in a multi-center study with a larger sample size.</description><issn>1664-2295</issn><issn>1664-2295</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpNkE1Lw0AYhBdRbKm9e5L9A6n7mXR7kRg_UigIpfey2X23rqZJ2E0KxT9vpQrOZWZgeA6D0C0lM87n6t41MIQZI1TNCEmpuEBjmqYiYUzJy395hKYxfpCTuFI85ddoxClLuRDZGH2Vqzx5xJQvCMU6Yo3XPn7ivK6hBuzagPOm99D5GrreG_wUhl1Mlo0dDFhcDL1uoB0izu0BQgS8Bm163zZxgUu_e4dw5v2AitDGmJwHB98fH27QldN1hOmvT9Dm5XlTlMnq7XVZ5KukU7xPGJEZy8BSJ8BloOeaWWe0sEyemmKpZaYyWZZyqZxiykiiuSSSGdCi4hWfoLszthuqPdhtF_xeh-P27wT-DYI5YB0</recordid><startdate>2019</startdate><enddate>2019</enddate><creator>Min, Fu-Li</creator><creator>Mao, Bi-Jun</creator><creator>Zheng, Zhong-Zheng</creator><creator>He, Na</creator><creator>Fan, Cui-Xia</creator><creator>Cai, Rui-Yan</creator><creator>Wang, Juan</creator><creator>Ou, Yang-Mei</creator><creator>Qin, Bing</creator><creator>Liao, Wei-Ping</creator><creator>Yi, Yong-Hong</creator><creator>Li, Ze</creator><creator>Shi, Yi-Wu</creator><scope>NPM</scope></search><sort><creationdate>2019</creationdate><title>HLA-B 13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?</title><author>Min, Fu-Li ; Mao, Bi-Jun ; Zheng, Zhong-Zheng ; He, Na ; Fan, Cui-Xia ; Cai, Rui-Yan ; Wang, Juan ; Ou, Yang-Mei ; Qin, Bing ; Liao, Wei-Ping ; Yi, Yong-Hong ; Li, Ze ; Shi, Yi-Wu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p93t-205727ed1f4ef7ea8a2dfca4d257ea926d2cbc776359f929c50a35052cea4b3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Min, Fu-Li</creatorcontrib><creatorcontrib>Mao, Bi-Jun</creatorcontrib><creatorcontrib>Zheng, Zhong-Zheng</creatorcontrib><creatorcontrib>He, Na</creatorcontrib><creatorcontrib>Fan, Cui-Xia</creatorcontrib><creatorcontrib>Cai, Rui-Yan</creatorcontrib><creatorcontrib>Wang, Juan</creatorcontrib><creatorcontrib>Ou, Yang-Mei</creatorcontrib><creatorcontrib>Qin, Bing</creatorcontrib><creatorcontrib>Liao, Wei-Ping</creatorcontrib><creatorcontrib>Yi, Yong-Hong</creatorcontrib><creatorcontrib>Li, Ze</creatorcontrib><creatorcontrib>Shi, Yi-Wu</creatorcontrib><collection>PubMed</collection><jtitle>Frontiers in neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Min, Fu-Li</au><au>Mao, Bi-Jun</au><au>Zheng, Zhong-Zheng</au><au>He, Na</au><au>Fan, Cui-Xia</au><au>Cai, Rui-Yan</au><au>Wang, Juan</au><au>Ou, Yang-Mei</au><au>Qin, Bing</au><au>Liao, Wei-Ping</au><au>Yi, Yong-Hong</au><au>Li, Ze</au><au>Shi, Yi-Wu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HLA-B 13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?</atitle><jtitle>Frontiers in neurology</jtitle><addtitle>Front Neurol</addtitle><date>2019</date><risdate>2019</risdate><volume>10</volume><spage>614</spage><pages>614-</pages><issn>1664-2295</issn><eissn>1664-2295</eissn><abstract>Antiepileptic drugs frequently cause cutaneous adverse reactions (cADRs). Numerous studies have reported associations between human leukocyte antigen (HLA) alleles and cADRs caused by single antiepileptic drug in Southern Han Chinese people. However, the relationship between the HLA allele and cADRs sequentially induced by two or more antiepileptic drugs (AEDs-induced cross-reactivity) is unclear. To explore the associations between HLA alleles and AEDs-induced cross-reactivity, we prospectively recruited patients with AEDs-induced cross-reactivity from 2009 to 2017 and performed high-resolution genotyping to detect the HLA-A, B, C, and DRB1 alleles in patients for comparison with normal controls. To verify the important genotype, we compared its presence in patients with cross-reactivity to enlarged normal controls, and its presence in patients with carbamazepine (CBZ)-induced maculopapular exanthema (MPE) to CBZ-tolerant controls. Further, the important allele was replicated by meta-analysis. Twenty-three patients with AED-induced cross-reactivity and 500 healthy individuals were enrolled from Southern China. All patients had a mild rash without mucosal or systemic involvement. The HLA-B 13:01 allele was present in 34.78% (8/23) of patients, 14.60% (73/500) of healthy individuals, and 14.5% (763/5,270) healthy individuals, revealing a significant association (8/23 vs. 73/500; = 0.02; OR: 3.12; 95% CI: 1.28-7.62; 8/23 vs. 763/5,270; = 0.014; OR: 3.15; 95% CI: 1.33-7.46). HLA-B 13:01 was presented numerically higher in CBZ-induced MPE than that in CBZ-tolerant individuals without statistical significance (33/145, 22.76%, vs. 28/179, 15.64%; = 0.103). Meta-analysis revealed an association between HLA-B 13:01 and cADRs induced by single AEDs or/and non-AEDs in Chinese and Thai populations ( = 0.000). This study suggests that HLA-B 13:01 is potentially associated with AED-cADRs in general, possibly with stronger effect in cross-reactivity. Screening for HLA-B 13:01 prior to starting AEDs therapy may help to avoid cADRs. However, this association requires further analysis in a multi-center study with a larger sample size.</abstract><cop>Switzerland</cop><pmid>31263447</pmid><doi>10.3389/fneur.2019.00614</doi></addata></record>
fulltext fulltext
identifier ISSN: 1664-2295
ispartof Frontiers in neurology, 2019, Vol.10, p.614
issn 1664-2295
1664-2295
language eng
recordid cdi_pubmed_primary_31263447
source PubMed Central
title HLA-B 13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A24%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HLA-B%2013:01%20as%20a%20Risk%20Allele%20for%20Antiepileptic%20Drugs-Induced%20Cutaneous%20Adverse%20Reactions:%20Higher%20Risk%20for%20Cross-Reactivity?&rft.jtitle=Frontiers%20in%20neurology&rft.au=Min,%20Fu-Li&rft.date=2019&rft.volume=10&rft.spage=614&rft.pages=614-&rft.issn=1664-2295&rft.eissn=1664-2295&rft_id=info:doi/10.3389/fneur.2019.00614&rft_dat=%3Cpubmed%3E31263447%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p93t-205727ed1f4ef7ea8a2dfca4d257ea926d2cbc776359f929c50a35052cea4b3b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/31263447&rfr_iscdi=true